The Identification of Pretreatment Trajectories of Alcohol Use and Their Relationship to Treatment Outcome in Men and Women With Alcohol Use Disorder

被引:11
|
作者
Stasiewicz, Paul R. [1 ]
Bradizza, Clara M. [1 ]
Ruszczyk, Melanie U. [1 ]
Lucke, Joseph F. [2 ]
Zhao, Junru [1 ]
Linn, Braden [3 ]
Slosman, Kim S. [1 ]
Dermen, Kurt H. [2 ]
机构
[1] SUNY Buffalo, Sch Social Work, 1021 Main St, Buffalo, NY 14203 USA
[2] SUNY Buffalo, Dept Psychiat, Buffalo, NY USA
[3] SUNY Buffalo, Clin & Res Inst Addict, Buffalo, NY USA
来源
基金
美国国家卫生研究院;
关键词
Pretreatment Change; Alcohol Use Disorder; Alcohol; Treatment; Behavior Change; RANDOMIZED-TRIAL; SELF-REPORTS; DRINKING; RELIABILITY; SCALE; CONSUMPTION; VALIDATION; MOTIVATION; READINESS; DRINKERS;
D O I
10.1111/acer.14216
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background Few studies have focused on behavioral changes that occur prior to entering treatment for an alcohol use disorder (AUD). In 2 studies (Psychol Addict Behav, 27, 2013, 1159; J Stud Alcohol, 66, 2005, 369), pretreatment reductions in alcohol use were associated with better treatment outcomes. Identifying patterns of pretreatment change has the potential to inform clinical decision making. Methods This study sought to identify pretreatment change trajectories in individuals seeking outpatient treatment for AUD (N = 205) using finite mixture modeling based on changes in number of days abstinent per week (NDA). Results The analysis identified 3 pretreatment trajectory classes. Class 1 (High Abstinence-Minimal Increase; HA-MI) (n = 64; 31.2%) reported a high level of pretreatment NDA with minimal change during an 8-week pretreatment interval. Class 2 (Low Abstinence-Steady Increase; LA-SI) (n = 73; 35.6%) reported a low level of pretreatment NDA followed by a steady increase beginning 2 weeks prior to the phone screen. Class 3 (Nonabstinent-Accelerated Increase; NA-AI) (n = 68; 33.2%) reported no or very low levels of pretreatment NDA but demonstrated an increase following the phone screen. With regard to within-treatment change, Class 1 demonstrated the least and Class 3 demonstrated the most change in NDA. From baseline to 6-month follow-up, Class 3 added 2.31 abstinent days per week, Class 2 added 0.69 days, and Class 1 added 0.63 days. The increase in NDA for Class 3 was significantly different from the other 2 classes; however, Class 3 reported fewer overall days abstinent at 6-month follow-up. Conclusions Study results have clinical and research implications including recommended changes to treatment protocols and research designs. Understanding the impact of pretreatment trajectories of alcohol use on within-treatment and posttreatment outcomes may provide important information about adapting treatment to increase efficiency and effectiveness.
引用
收藏
页码:2637 / 2648
页数:12
相关论文
共 50 条
  • [21] Alcohol Use Disorder in the Age of Technology: A Review of Wearable Biosensors in Alcohol Use Disorder Treatment
    Davis-Martin, Rachel E.
    Alessi, Sheila M.
    Boudreaux, Edwin D.
    [J]. FRONTIERS IN PSYCHIATRY, 2021, 12
  • [22] Treatment Resistant Alcohol Use Disorder
    Patterson Silver Wolf, David A.
    Dulmus, Catherine N.
    Wilding, Gregory E.
    Yu, Jihnhee
    Barczykowski, Amy L.
    Shi, Tiange
    Diebold, Josal R.
    Harvey, Steven J.
    Tomasello, Nicole M.
    Linn, Braden K.
    [J]. ALCOHOLISM TREATMENT QUARTERLY, 2022, 40 (02) : 205 - 216
  • [23] Outpatient treatment of alcohol use disorder
    Molavi, Armon
    Guruge, Sulara
    Kelly, Peter
    [J]. BRITISH COLUMBIA MEDICAL JOURNAL, 2020, 62 (08): : 272 - 276
  • [24] "Evidence" and the Treatment of Alcohol Use Disorder
    Howland, Robert H.
    [J]. JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES, 2015, 53 (05) : 11 - 14
  • [25] Zonisamide Treatment of Alcohol Use Disorder
    Arias, Albert
    Covault, Jonathan
    Kranzler, Henry
    Feinn, Richard
    Ralevski, Elizabeth
    Tennen, Howard
    Petrakis, Ismene
    [J]. NEUROPSYCHOPHARMACOLOGY, 2021, 46 (SUPPL 1) : 413 - 413
  • [26] Semaglutide for Treatment of Alcohol Use Disorder
    Royal, Kyleigh
    Khorgami, Zhamak
    Simmons, William
    Richards, Jesse
    [J]. OBESITY, 2023, 31 : 185 - 185
  • [27] Psilocybin for Treatment of Alcohol Use Disorder
    Slomski, Anita
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 328 (13): : 1288 - 1288
  • [28] Semaglutide for Treatment of Alcohol Use Disorder
    Neuman, Taylor
    Corrado, Richele
    Banaag, Amanda
    Koehlmoos, Tracey
    [J]. OBESITY, 2023, 31 : 185 - 186
  • [29] Gabapentin for the treatment of alcohol use disorder
    Mason, Barbara J.
    Quello, Susan
    Shadan, Farhad
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (01) : 113 - 124
  • [30] Pharmacologic treatment of alcohol use disorder
    Finley, Caitlin R.
    Rumley, Carly
    Korownyk, Christina S.
    [J]. CANADIAN FAMILY PHYSICIAN, 2020, 66 (08) : 583 - 583